853 completed. 853 Phase 2, 111 Phase 1, 22 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 853 | Completed 853 |
| Phase 1 | 111 | Completed 111 |
| Phase 3 | 22 | Completed 22 |
Follow Cisplatin: new trials by email Literature Review of Cisplatin trials Research Report on Cisplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal Carcinoma Toripalimab (240mg day1, Q3W*3cycle), Cisplatin (80 mg/m2), Nab-paclitaxel - Nasopharyngeal Carcinoma (NPC), Radiation-induced Oral Mucositis | Phase 2 | Completed | Affiliated Hospital of Guangdong Medical University | 210 | 2024-11-01 | 2026-11-05 |
| TIP Regimen Combined With Toripalimab Neoadjuvant Therapy for Locally Advanced Penile Cancer Paclitaxel + Ifosfamide + Cisplatin & Toripalimab - Penile Cancer | Phase 2 | Completed | Sun Yat-sen University | 25 | 2024-05-31 | 2026-10-13 |
| Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy - Esophageal Squamous Cell Carcinoma, Efficacy | Phase 2 | Completed | Sun Yat-sen University | 170 | 2024-02-15 | 2026-08-03 |
| Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma gemcitabine, Cisplatin - Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma | Phase 2 | Completed | Yung NA | 15 | 2024-02-02 | 2026-10-28 |
| An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer. Cisplatin 40 mg/m2, Cisplatin 100 mg/m2 - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 60 | 2024-01-01 | 2026-10-16 |
| A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer Xevinapan, Cisplatin, External beam - Head and Neck Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 4 | 2023-11-16 | 2026-08-10 |
| The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC definitive radiotherapy, induction chemo-immunotherapy, concurrent chemotherapy - Non-small Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 114 | 2023-07-25 | 2026-08-03 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer Tislelizumab, Ociperlimab, Alcestobart - Non Small Cell Lung Cancer | Phase 2 | Completed | BeiGene | 121 | 2023-03-08 | 2026-02-09 |
| A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer Tislelizumab, BGB-A445, LBL-007 - Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 2 | Completed | BeiGene | 418 | 2023-02-10 | 2026-10-30 |
| JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection, Toripalimab, Docetaxel - Advanced Lung Cancer | Phase 1 / Phase 2 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 119 | 2023-02-09 | 2025-12-02 |
| PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer Tislelizumab - Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 118 | 2023-01-13 | 2025-08-24 |
| TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection, TQB2618 injection; Penpulimab injection - Nasopharyngeal Carcinoma | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 47 | 2022-10-27 | 2026-04-07 |
| Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients cisplatin with hydration magnesium, cisplatin 40 mg/m² - Cisplatin Adverse Reaction | Phase 2 | Completed | Tanta University | 100 | 2022-10-01 | 2026-03-23 |
| Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC Nab-paclitaxel, Cisplatin, Tislelizumab - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | West China Hospital | 40 | 2022-09-12 | 2025-05-22 |
| A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC GFH018, Toripalimab, Paclitaxel - NSCLC, Stage III | Phase 2 | Completed | Genfleet Therapeutics (Shanghai) Inc. | 65 | 2022-09-09 | 2025-10-02 |
| A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors LBL-007 Injection, Tislelizumab Injection, Cisplatin Injection - Malignant Tumors | Phase 1 / Phase 2 | Completed | Nanjing Leads Biolabs Co.,Ltd | 98 | 2022-09-01 | 2026-04-01 |
| A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM PM8002, Pemetrexed, Cisplatin - MPM | Phase 2 | Completed | Biotheus Inc. | 31 | 2022-08-13 | 2026-06-08 |
| A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors BMS-986408, Nivolumab, Ipilimumab - Advanced Solid Tumors | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 68 | 2022-08-02 | 2026-08-13 |
| A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors AK104, AK117, Capecitabine tablets - Advanced Malignant Tumors | Phase 1 / Phase 2 | Completed | Akeso | 128 | 2022-03-12 | 2026-06-11 |
Showing 20 of 853. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (136) · Head and Neck Neoplasms (90) · Squamous Cell Carcinoma of Head and Neck (74) · Lung Neoplasms (69) · Stomach Neoplasms (68) · Esophageal Neoplasms (61) · Urinary Bladder Neoplasms (38) · Breast Neoplasms (32) · Uterine Cervical Neoplasms (32) · Pancreatic Neoplasms (31) · Esophageal Squamous Cell Carcinoma (30) · Adenocarcinoma Of Esophagus (28) · Neoplasm Metastasis (26) · Neoplasms (25) · Ovarian Neoplasms (23)
Eli Lilly and Company (50) · Memorial Sloan Kettering Cancer Center (42) · National Cancer Institute (NCI) (37) · Radiation Therapy Oncology Group (20) · M.D. Anderson Cancer Center (19) · Dana-Farber Cancer Institute (18) · Alliance for Clinical Trials in Oncology (15) · European Organisation for Research and Treatment of Cancer - EORTC (14) · Sanofi (14) · Hoffmann-La Roche (12) · Swiss Cancer Institute (12) · Fudan University (11) · SWOG Cancer Research Network (11) · Sun Yat-sen University (11) · Asan Medical Center (10)
United States (433) · China (94) · France (77) · Germany (70) · Spain (66) · Canada (61) · Italy (55) · South Korea (52) · United Kingdom (51) · Belgium (37) · Netherlands (30) · Switzerland (30) · Poland (27) · Taiwan (26) · Australia (21)
David H. Ilson, MD, PhD (6) · Corey J. Langer, MD (5) · David J. Adelstein, MD (5) · Douglas Adkins, M.D. (4) · Dung Le, MD (4) · Erkut Borazanci, MD (4) · Everett Vokes, MD (4) · Michele Reni, MD (4)
PMID 25057165, PMID 25366678, PMID 28742685, PMID 28797458, PMID 30267838, PMID 31401903, PMID 32017652, PMID 33358660, PMID 10811668, PMID 11208820, PMID 11241082, PMID 11398890, PMID 11573045, PMID 11835236, PMID 11886723, PMID 11904735, PMID 12167786, PMID 12518365, PMID 12607634, PMID 12717353, PMID 12721251, PMID 12771884, PMID 1403051, PMID 14630682, PMID 14666038, PMID 14967461, PMID 15047228, PMID 15142632, PMID 15297403, PMID 15310778, PMID 15386331, PMID 15542799, PMID 15667956, PMID 15735120, PMID 15803016, PMID 1584260, PMID 15860857, PMID 15863167, PMID 15865075, PMID 15999102, PMID 15999362, PMID 16149148, PMID 16170174, PMID 16170182, PMID 16249022, PMID 16361622, PMID 16399443, PMID 16445649, PMID 16467544, PMID 16532436
U10CA032102 (11), 2008 (8), P30CA043703 (8), U10CA021115 (8), U10CA031946 (8), 2014 (5), 2017 (5), 2018 (5), P30CA008748 (5), 2009 (4), 2015 (4), P30CA015083 (4), P30CA022453 (4), U10CA180820 (4), 2005 (3)